Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma

Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma

Background: Regorafenib is a second-line therapy drug used for advanced hepatocellular carcinoma (HCC). Unfortunately, the survival benefit of the patients receiving this treatment is modest, which may be attributed to drug resistance. In the present study, sphingosine kinase 2 (SphK2) was targeted...

Full description

Bibliographic Details
Main Authors: Weiwei Shi, Shan Zhang, Ding Ma, Dongliang Yan, Guang Zhang, Yin Cao, Zhongxia Wang, Junhua Wu, Chunping Jiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Oncology
Subjects:
sphingosine kinase 2
sphingosine-1-phosphate
ABC294640
regorafenib
resistance
hepatocellular carcinoma
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00694/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00694/full

Similar Items